Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are expected in 2025.

No one thinks their life can turn on a dime, but Lillian Green went from a fiercely independent mother to an exhausted cancer ...

Partial nephrectomy showed similar overall and cancer-specific survival rates to radiofrequency ablation in patients with ...

Independent Data Safety Monitoring Board declared dose level 2 as safe and recommended escalation to final dose level 3Munich, Germany – December ...

Severe vivax malaria, once considered a relatively benign infection compared to its counterpart P. falciparum, has emerged as a significant health concern with severe and life-threatening ...

Acute kidney injury (AKI) often occurs as a result of ischemia, which is a condition in which blood flow to part of the body ...

With new CDC data expressing optimism about the epidemic of sexually transmitted infections (STIs), take a look at the ...

A noninvasive urinary biomarker panel predicts lupus nephritis activity and response better than proteinuria, and, if further validated, may aid diagnosis and gauge treatment response, investigators ...

We are thankful for the steady pace of site activations and continued brisk enrollment with our recently activated sites already contributing,” said Kevin Chung, MD, Chief Medical Officer of SeaStar ...

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of ...